Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Orion

Thumbnail
October 21, 2020

Amylyx provides hope in amyotrophic lateral sclerosis

Amylyx believes it has found a disease-modifying therapy in AMX0035, as other key readouts approach.

Thumbnail
July 24, 2019

Biogen leads the way in renewed amyotrophic lateral sclerosis push

The company has quietly emerged as the key player to watch in an area that has seen several setbacks of late.

Article image
Vantage logo
February 14, 2019

Asco-GU 2019 – Bayer and Orion have their work cut out with darolutamide

Results of the prostate cancer project’s pivotal Aramis trial, already known to be positive, are presented for the first time.

Article image
Vantage logo
January 31, 2019

Titan could give Erleada a fighting chance

But Erleada, Johnson & Johnson’s next-gen prostate cancer therapy, still needs to outperform the incumbent, Zytiga.

Article image
Vantage logo
December 17, 2018

Lilly buys into ion channels – again

Article image
Vantage logo
August 24, 2018

Upcoming events – Pivotal data readouts for Galapagos and Bayer

Galapagos and Bayer/Orion will both report phase III data this quarter – the former with filgotinib in arthritis and the latter with darolutamide in prostate cancer.

Vantage logo
November 22, 2017

Therapy focus – Cytokinetics crash puts spotlight on new ALS approaches

Vantage logo
November 13, 2017

Alnylam: The $12bn company with the $2bn war chest

Vantage logo
August 29, 2017

ESC 2017 – Medicines Company forges on alone

Vantage logo
August 23, 2017

ESC 2017 preview – What outcomes might mean for incomes

Vantage logo
March 18, 2017

ACC – As Amgen goes, so goes Medicines Company

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
February 10, 2021

2020 wins top of the froths for biotech stocks

Vantage logo
October 04, 2018

Biotech flotations remain in high demand

Vantage logo
February 04, 2021

Glaxo’s growth problem

Vantage logo
January 27, 2021

Go or no go? Oncology decisions ahead for the FDA

Vantage logo
February 05, 2021

Pfizer reveals its PD-1 secret

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.